Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants
Journal of Acquired Immune Deficiency Syndromes - United States
doi 10.1097/qai.0000000000001031
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2016
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)